Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | Director | August 18, 2026 | August 20, 2026 |
| Lifeward Ltd.RWLK · Entity 7620 | Director | June 27, 2017 | June 29, 2017 |
| Neuronetics, Inc.STIM · Entity 6248 | Director | May 28, 2026 | May 29, 2026 |
| REPLIGEN CORPRGEN · Entity 486 | Director | May 14, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,086 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Exercise / conversion · Acquired 3,086 · Balance 3,086 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 52,469 |
Reported balance
After 2026-08-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-18 · Exercise / conversion · Disposed 3,086 · Balance 52,469 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter.
Lifeward Ltd.
Report date June 27, 2017 · Filed June 29, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2027-06-27 | Direct | 4,176 |
Reported balance
After 2017-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-27 · Grant · Acquired 4,176 · Balance 4,176 F1: Represents stock options granted under the ReWalk 2014 Equity Incentive Plan on June 27, 2017. The options become vested and exercisable in four equal quarterly installments starting three months following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options granted under the ReWalk 2014 Equity Incentive Plan on June 27, 2017. The options become vested and exercisable in four equal quarterly installments starting three months following the date of grant.
Neuronetics, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 401,816 |
Reported balance
After 2026-05-28 transaction · row 1
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 30,000 · Balance 401,816 F1: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2027 or (b) the Reporting Person's Board-approved separation of service from the Issuer or change in control of the Issuer, in each case subject to continuous service of the Reporting Person through such date. F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2027 or (b) the Reporting Person's Board-approved separation of service from the Issuer or change in control of the Issuer, in each case subject to continuous service of the Reporting Person through such date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
REPLIGEN CORP
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,051 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 995 · Balance 40,051 F1: Mr. Muir was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.38 · Expires 2036-05-14 | Direct | 2,239 |
Reported balance
After 2026-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-14 · Grant · Acquired 2,239 · Balance 2,239 F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Muir was awarded 995 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 14, 2027, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The Reporting Person has elected to defer settlement of these restricted stock units pursuant to the Repligen Corporation Deferred Compensation Plan for Non-Employee Directors. Once vested, the shares will be issued in accordance with the Reporting Person's deferral election following the separation of the Reporting Person's service as a Director. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2: Award vests in full on the earlier of May 14, 2027, one year from grant date, or on the date of the next annual meeting of the Company's shareholders, which has not yet been determined.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
G1 Therapeutics, Inc.
Report date September 18, 2024 · Filed September 18, 2024
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-09-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-09-18 · Disposition to issuer · Disposed 20,000 · Balance 185,358 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration"). F2: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration. Row 2 · 2024-09-18 · Other · Disposed 185,358 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.83 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.30 · Expires 2032-06-23 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-09-18 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2025-09-07 | Direct | 0 |
Reported balance
After 2024-09-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-09-18 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 6, 2024, among the Issuer, Pharmacosmos A/S, a Danish Aktieselskab ("Parent"), and Genesis Merger Sub, Inc. ("Purchaser"), an indirect wholly-owned subsidiary of Parent, Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of September 18, 2024, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive $7.15 per share in cash, without interest and subject to any applicable withholding taxes (the "Merger Consideration").
F2: (Continued from footnote 1) Pursuant to the Merger Agreement, at the Effective Time, each outstanding deferred stock unit (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration.
F3: Pursuant to the Merger Agreement, at the Effective Time, each share of common stock held by the Reporting Person was tendered in exchange for the Merger Consideration.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each "Stock Option") that was outstanding immediately prior to the Effective Time became fully vested and was cancelled at the Effective Time and converted into the right to receive an amount in cash equal to the product of (x) the total number of shares of common stock subject to such Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Merger Consideration over the applicable exercise price per share under such Stock Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2021 Filed May 18, 2021 01:57 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 457 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-019712 · doc4.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,362 F1 · shares: Mr. Muir was awarded 457 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on the earlier of May 13, 2022, one year from the grant date, or the date of the next annual meeting of the Company's shareholders, which has not yet been determined. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 21:54 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | PurchaseCommon Stock | 50,000 | $13.50 | $675,000.00 |
DisclosureSEC source: 0001562180-20-006801 · primarydocument.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,969 Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 21:07 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 18,513 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-20-000647 · edgar.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,236 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) August 5, 2021, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:39 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.59 | $0.00 |
DisclosureSEC source: 0001209191-20-036301 · doc4.xml · derivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 11, 2020, subject to the Reporting Person's continued service as a director. Read SEC document |
| May 26, 2020 Filed May 28, 2020 20:51 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001192482-20-000412 · edgar.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,723 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 26, 2021, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 13, 2020 Filed May 20, 2020 00:42 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 1,285 | $0.00 Strike: $128.18 | $0.00 |
DisclosureSEC source: 0000899243-20-013632 · doc4.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,285 Underlying: Common Stock · 1,285 shares Expires 2030-05-13 F2 · derivative.exercise_date: Award vests in full one year from grant date on May 13, 2021. Read SEC document |
| May 13, 2020 Filed May 20, 2020 00:42 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 527 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-013632 · doc4.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,905 F1 · shares: Mr. Muir was awarded 527 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 13, 2021. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 20:32 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $18.47 | $0.00 |
DisclosureSEC source: 0001209191-19-037146 · doc4.xml · derivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 12, 2019, subject to the Reporting Person's continued service as a director. Read SEC document |
| May 28, 2019 Filed May 30, 2019 20:50 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantStock Option (right to buy) · Derivative | 7,347 | $0.00 Strike: $13.43 | $0.00 |
DisclosureSEC source: 0001209191-19-033453 · doc4.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,347 Underlying: Common Stock · 7,347 shares Expires 2029-05-27 F3 · derivative.exercise_date: The option shall vest on the earlier of (a) May 28, 2029, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. Read SEC document |
| May 28, 2019 Filed May 30, 2019 20:50 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantCommon Stock | 3,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-033453 · doc4.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,723 F1 · shares: Represents a restricted stock unit ("RSU") award that vests on the earlier of (a) May 28, 2029, and (b) the Company's next annual meeting of stockholders, in each case subject to continuous service of the Reporting Person through such date. F2 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:10 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,109 | $0.00 Strike: $67.71 | $0.00 |
DisclosureSEC source: 0000899243-19-013990 · doc4.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,109 Underlying: Common Stock · 2,109 shares Expires 2029-05-15 F2 · derivative.exercise_date: Award vests in full one year from grant date on May 15, 2020. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:10 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-013990 · doc4.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,378 F1 · shares: Mr. Muir was awarded 923 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 15, 2020. The restricted stock units may be settled only be delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:38 UTC | Neuronetics, Inc. STIM · Entity 6248 | GrantStock Option (Right to Buy) · Derivative | 8,767 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001209191-18-041659 · doc4.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,767 Underlying: Common Stock · 8,767 shares Expires 2028-04-24 F1 · derivative.exercise_date: The performance criterion for vesting of this option was met upon the closing of the Issuer's initial public offering. One twelfth (1/12th) of the shares subject to the option vested or shall vest monthly commencing on March 16, 2018, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:38 UTC | Neuronetics, Inc. STIM · Entity 6248 | PurchaseCommon Stock | 40,000 | $17.00 | $680,000.00 |
DisclosureSEC source: 0001209191-18-041659 · doc4.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 16:13 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $38.39 | $0.00 |
DisclosureSEC source: 0001209191-18-036867 · doc4.xml · derivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-07 F1 · derivative.exercise_date: The shares underlying this option will vest in their entirety twelve months after June 7, 2018, subject to the Reporting Person's continued service as a director. Read SEC document |
| May 16, 2018 Filed May 17, 2018 20:44 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 3,304 | $0.00 Strike: $42.07 | $0.00 |
DisclosureSEC source: 0001140361-18-024450 · doc1.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,304 Underlying: Common Stock · 3,304 shares Expires 2028-05-16 F2 · derivative.exercise_date: Award vests in full one year from grant date on May 16, 2019. Read SEC document |
| May 16, 2018 Filed May 17, 2018 20:44 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 1,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-024450 · doc1.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,455 F1 · shares: Mr. Muir was awarded 1,486 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest on May 16, 2019. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| July 11, 2017 Filed Jul 13, 2017 23:41 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0001209191-17-045118 · doc4.xml · derivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-07-11 F1 · derivative.exercise_date: The stock option will vest in thirty-six monthly installments at the end of each successive month following July 11, 2017, subject to the Reporting Person's continued service as a director. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 13:11 UTC | Lifeward Ltd. RWLK · Entity 7620 | GrantOption (Right to buy) · Derivative | 4,176 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001628280-17-006805 · wf-form4_149874186104195.xml · derivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,176 Underlying: Ordinary Shares, par value NIS 0.01 per share · 4,176 shares Expires 2027-06-27 F1 · derivative.exercise_date: Represents stock options granted under the ReWalk 2014 Equity Incentive Plan on June 27, 2017. The options become vested and exercisable in four equal quarterly installments starting three months following the date of grant. Read SEC document |
| May 22, 2017 Filed May 24, 2017 23:58 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | ConversionSeries C Preferred Stock · Derivative | 302,908 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-035152 · doc4.xml · derivative · entry 3 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Amended and Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Amended and Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. F3 · derivative.exercise_date: The Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date. F3 · derivative.expiration_date: The Series C Preferred Stock automatically converted into shares of Common Stock upon consummation of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 22, 2017 Filed May 24, 2017 23:58 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | PurchaseCommon Stock | 20,000 | $15.00 | $300,000.00 |
DisclosureSEC source: 0001209191-17-035152 · doc4.xml · nonDerivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,969 F2 · price: Reflects shares the reporting person purchased in the initial public offering at the initial public offering price of $15.00 per share. Read SEC document |
| May 22, 2017 Filed May 24, 2017 23:58 UTC | G1 Therapeutics, Inc. GTHX · Entity 87413 | ConversionCommon Stock | 100,969 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-035152 · doc4.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Preferred Stock automatically converted into Common Stock upon the closing of the Issuer's initial public offering pursuant to the Issuer's Fifth Amended and Restated Certificate of Incorporation, as amended, based on the conversion rate in effect at the time of conversion. The Series C Preferred Stock converted to Common Stock on a 1-for-3 basis. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:02 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 2,434 | $0.00 Strike: $38.76 | $0.00 |
DisclosureSEC source: 0001140361-17-021759 · doc1.xml · derivative · entry 2 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,434 Underlying: Common Stock · 2,434 shares Expires 2027-05-18 F2 · derivative.exercise_date: Award vests in full one year from grant date on May 18, 2018. Read SEC document |
| May 18, 2017 Filed May 22, 2017 21:02 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 1,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-021759 · doc1.xml · nonDerivative · entry 1 MUIR GLENN P · CIK 0001181190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,969 F1 · shares: Mr. Muir was awarded 1,206 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest on May 18, 2018. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.